Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
6.10
-0.32 (-4.98%)
At close: Aug 13, 2025, 4:00 PM
6.17
+0.07 (1.10%)
Pre-market: Aug 14, 2025, 8:04 AM EDT
Immatics Revenue
Immatics had revenue of 4.74M EUR in the quarter ending June 30, 2025, a decrease of -74.74%. This brings the company's revenue in the last twelve months to 130.13M, up 83.61% year-over-year. In the year 2024, Immatics had annual revenue of 155.84M with 188.60% growth.
Revenue (ttm)
130.13M EUR
Revenue Growth
+83.61%
P/S Ratio
4.62
Revenue / Employee
190,805 EUR
Employees
682
Market Cap
741.46M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 155.84M | 101.84M | 188.60% |
Dec 31, 2023 | 54.00M | -118.83M | -68.76% |
Dec 31, 2022 | 172.83M | 138.07M | 397.17% |
Dec 31, 2021 | 34.76M | 3.51M | 11.23% |
Dec 31, 2020 | 31.25M | 12.80M | 69.40% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IMTX News
- 1 day ago - Immatics Announces Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma - GlobeNewsWire
- 3 months ago - Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 4 months ago - Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - GlobeNewsWire
- 4 months ago - Immatics N.V.: Trading Below Cash, But Not Without Reason - Seeking Alpha
- 5 months ago - Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewsWire
- 9 months ago - Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - GlobeNewsWire
- 9 months ago - Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - GlobeNewsWire